HIT Typ II in der operativen Medizin ... - Vascularcare.de

[74] Kodityal S, Manhas AH, Udden M, Rice L: Danaparoid for heparininducedthrombocytopenia: an analysis of treatment failures. Eur JHaematol 71 (2003) 109–13[75] Koster A, Hansen R, Kuppe H, Hetzer R, Crystal GJ, Mertzlufft F:Recom-binant hirudin as an alternative for anticoagulation duringcardiopulmonary bypass in patients with heparin-inducedthrombocytopenia type II: a 1-year experience in 57 patients.J Cardiothorac Vasc Anesth 14 (2000) 243–48[76] Koster A, Sanger S, Hansen R, Sodian R, Mertzlufft F, Harke C,Kuppe H, Hetzer R, Loebe M: Prevalence and persistence ofheparin/platelet factor 4 antibodies in patients with heparincoated and noncoated ventricular assist devices. ASAIO J 46(2000) 319–22[77] Koster A, Spiess B, Chew DP, Krabatsch T, Tambeur L, DeAnda A,Hetzer R, Kuppe H, Smedira NG, Lincoff AM: Effectiveness ofbivalirudin as a replacement for heparin during cardiopulmonarybypass in patients undergoing coronary artery bypass grafting.Am J Cardiol 93 (2004) 356-9[78] Kozek-Langenecker SA, Spiss CK, Gamsjager T, Domenig C,Zimpfer M: Anticoagulation with prostaglandins and unfractionatedheparin during continuous venovenous haemofiltration: a randomizedcontrolled trial. Wien Klin Wschr 114 (2002) 96–101[79] Kozek-Langenecker SA, Spiss CK, Michalek-Sauberer A, FelfernigM, Zimpfer M: Effect of prostacyclin on platelets, polymorphonuclearcells, and heterotypic cell aggregation during hemofiltration.Crit Care Med 31 (2003) 864–68[80] Kramer L, Bauer E, Joukhadar C, Strobl W, Gendo A, Madl C,Gangl A: Citrate pharmacokinetics and metabolism in cirrhoticand noncirrhotic critically ill patients. Crit Care Med 31 (2003)2450–55[81] Lagrange F, Brun JL, Vergnes MC, Paolucci F, Nadal T, Leng JJ,Saux MC, Bannwarth B: Fondaparinux sodium does not cross theplacental barrier: study using the in-vitro human dually perfusedcotyledon model. Clin Pharmacokinet 41 Suppl 2 (2002) 47–49[82] Langenecker SA, Felfernig M, Werba A, Mueller CM, Chiari A,Zimpfer M: Anticoagulation with prostacyclin and heparin duringcontinuous venovenous hemofiltration. Crit Care Med 22 (1994)1774–81[83] Langenecker SA, Felfernig M, Werba A, Mueller CM, Chiari A,Zimpfer M: Anticoagulation with prostacyclin and heparinduring continuous venovenous hemofiltration. Crit Care Med 22(1994) 1774–81[84] Lebrazi J, Elalamy I, Samama MM: In vitro effect of melagatranand lepirudin on clot-bound thrombin. Thromb Res 110 (2003)249–52[85] Lefevre G, Duval M, Gauron S, Brookman LJ, Rolan PE, Morris TM,Piraino AJ, Morgan JM, Palmisano M, Close P: Effect of renalimpairment on the pharmacokinetics and pharmacodynamics ofdesirudin. Clin Pharmacol Ther 62 (1997) 50–59[86] Lewis BE, Wallis DE, Leya F, Hursting MJ, Kelton JG, Argatroban-915 Investigators: Argatroban anticoagulation in patients withheparin-induced thrombocytopenia. Arch Intern Med 163 (2003)1849–56[87] Lincoff AM, Bittl JA, Kleiman NS, Sarembock IJ, Jackman JD,Mehta S, Tannenbaum MA, Niederman AL, Bachinsky WB, Tift-Mann J 3rd, Parker HG, Kereiakes DJ, Harrington RA, Feit F,Maierson ES, Chew DP, Topol EJ; REPLACE-1 Investigators.Comparison of bivalirudin versus heparin during percutaneouscoronary intervention (the Randomized Evaluation of PCI LinkingAngiomax to Reduced Clinical Events [REPLACE]-1 trial).Am J Cardiol 93 (2004) 1092-6[88] Lindhoff-Last E, Bauersachs R: Heparin-induced thrombocytopenia-alternativeanticoagulation in pregnancy and lactation. SeminThromb Hemost 28 (2002) 439–46[89] Lindhoff-Last E, Eichler P, Stein M, Plagemann J, Gerdsen F,Wagner R, Ehrly AM, Bauersachs R: A prospective study on theincidence and clinical relevance of heparin-induced antibodies inpatients after vascular surgery. Thromb Res 15, 97 (2000) 387–93[90] Lisman T, Bijsterveld NR, Adelmeijer J, Meijers JC, Levi M,Nieuwenhuis HK, de Groot PG: Recombinant factor VIIa reversesthe in vitro and ex vivo anticoagulant and profibrinolytic effectsof fondaparinux. J Thromb Haemost 1 (2003) 2368–73[91] Lucas FV, Skrinska VA, Chisolm GM, Hesse BL: Stability of prostacyclinin human and rabbit whole blood and plasma. Thromb Res43 (1986) 379–87[92] Macchi L, Sarfati R, Guicheteau M: Thromboembolic prophylaxiswith danaparoid (Orgaran) in a high-thrombosis-risk pregnantwoman with a history of heparin-induced thrombocytopenia (HIT)and Widal's disease. Clin Appl Thromb Hemost 6 (2000) 187–89[93] Maetzke J, Hinrichs R, Staib G, Scharffetter-Kochanek K:Fondaparinux as a novel therapeutic alternative in a patient withheparin allergy. Allergy 59 (2004) 237–38[94] Magnani HN: Heparin-induced thrombocytopenia (HIT): an overviewof 230 patients treated with orgaran (Org 10172). ThrombHaemost 70 (1993) 554–61[95] Markwardt F, Fink G, Kaiser B: Pharmacological survey of recombinanthirudin. Pharmazie 43 (1988) 202–7[96] Markwardt F: Untersuchungen über den Mechanismus der blutgerinnungshemmendenWirkung des Hirudins. N.-S. Arch Pharmacol229 (1956) 389–99VASCULAR CARE 1/2005 VOL. 8 51